Evommune refills its I&I pipeline with a $30M bet on a Chinese VAV1 degrader

Evommune needed a new oral drug. It went to China for one. On 5 November the company in-licensed EVO570, an oral molecular glue degrader of VAV1, from Hinova Pharmaceuticals, taking worldwide rights outside Greater China.

The terms

Evommune is paying $30 million upfront, split between $20 million in cash and $10 million in pre-funded warrants for its own stock. Hinova can earn up to about $1.1 billion in development, regulatory and commercial milestones, plus tiered royalties on sales outside Greater China.

Get Tx Weekly every TuesdayThree-minute read. Free. One-click unsubscribe.

The drug

VAV1 is a signalling protein found mainly in immune cells, where it helps switch on T and B cells. EVO570, previously called HC118 and known as HP570 in China, is built to remove it altogether. BioSpace reports the companies are pitching better safety and tolerability than JAK inhibitors, and that Oppenheimer analysts cite preclinical data showing about 20 times the potency of Novartis's MRT-6160, the VAV1 degrader it licensed from Monte Rosa.

"Adding this development-stage program is a strategic step for Evommune" Greg Moss, Chief Business and Legal Officer, Evommune

INDs have been submitted in China and accepted in the US. A Phase 1 study of safety, pharmacokinetics and target engagement is expected to start imminently, and Evommune plans a Phase 2 trial in rheumatoid arthritis in 2027.

Why now

Evommune's lead oral asset, EVO756, failed in mid-stage studies in chronic spontaneous urticaria and atopic dermatitis, and the company has stopped development in both. A mid-stage migraine trial carries on. That leaves a gap in near-term news, and BioSpace reports Oppenheimer now sees the company's story resting on its anti-IL-18 antibody, EVO301. A cheap, early-stage licence buys it a second shot in oral immunology without a big cash outlay.

The bigger picture

China remains the go-to shelf for early assets. In the same week, Boehringer Ingelheim agreed $358 million in upfront and near-term payments, with up to $7 billion more, for six preclinical cancer programmes from Sino Biopharmaceutical subsidiaries. BioPharma Dive keeps a running tracker of China licensing deals, and it keeps getting longer. For listed biotechs like Evommune, small upfronts and long milestone tails are the way to rebuild a pipeline quickly.

What it means for hiring

In-licensing from China puts a premium on people who can run cross-border CMC transfer and regulatory work between Chinese and US filings. Those profiles are already hard to find.
A company moving from a failed lead into a new Phase 1 needs early clinical development and translational immunology leaders who can set up fast. We'd expect Evommune and peers to be hiring in that area.
Search and evaluation teams that can spot assets like EVO570 early are now a competitive edge for I&I biotechs, not just for big pharma.

Share Ask Harry about this →